Skip to main content

Advertisement

Table 1 Baseline demographics (ITT population)

From: Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol

 Alirocumab (n = 128)Usual carea (n = 58)
Age, years, mean (SD)62.1 (9.5)63.4 (9.0)
Male, n (%)65 (50.8)28 (48.3)
Race, n (%)
 American Indian or Alaska Native3 (2.3)0
 Asian/Oriental2 (1.6)6 (10.3)
 Black4 (3.1)2 (3.4)
 Other3 (2.3)0
 White/Caucasian116 (90.6)50 (86.2)
Ethnicity, n (%)
 Hispanic or Latino17 (13.3)8 (13.8)
 Not Hispanic or Latino110 (85.9)50 (86.2)
 Not reported/unknown1 (0.8)0
Weight, kg, mean (SD)93.6 (19.7)93.8 (16.4)
BMI, kg/m2, mean (SD)32.6 (4.9)33.0 (4.6)
Systolic blood pressure, mmHg, mean (SD)130.0 (14.4)134.9 (15.7)
Diastolic blood pressure, mmHg, mean (SD)76.3 (9.8)77.2 (9.2)
ASCVD (CHD, ischemic stroke, PAD), n (%)47 (36.7)24 (41.4)
HbA1c, %, mean (SD)7.0 (0.9)7.3 (0.8)
Fasting plasma glucose, mg/dL, mean (SD)150.2 (39.2)153.2 (41.1)
Individuals receiving insulin at baseline, n (%)52 (40.6)26 (44.8)
Baseline lipids, mean (SD)
 Non-HDL-C, mg/dL170.3 (48.2)166.3 (48.8)
  mmol/L4.41 (1.25)4.31 (1.26)
 LDL-C (beta-quantification), mg/dL112.8 (43.7)110.7 (42.1)
  mmol/L2.92 (1.13)2.87 (1.09)
 ApoB, mg/dL109.3 (27.4)108.1 (28.9)
 LDL particle number, nmol/L1497.3 (532.0)1491.5 (545.1)
 Lipoprotein(a), mg/dL, median (Q1:Q3)18.0 (5.0:55.0)9.5 (4.0:30.0)
 TGs, mg/dL, median (Q1:Q3)281.5 (245.0:369.0)269.0 (232.0:328.0)
  mmol/L3.19 (2.77:4.17)3.04 (2.62:3.71)
 HDL-C, mg/dL34.4 (6.2)34.3 (5.9)
  mmol/L0.89 (0.16)0.89 (0.15)
  1. ASCVD atherosclerotic cardiovascular disease, ApoB apolipoprotein B, BMI body mass index, CHD coronary heart disease, HbA1c glycated hemoglobin, HDL-C high-density lipoprotein cholesterol, ITT intention-to-treat, LDL low-density lipoprotein, LDL-C low-density lipoprotein cholesterol, PAD peripheral artery disease, SD standard deviation, TG triglyceride
  2. aOptions included ezetimibe, fenofibrate, no additional lipid-lowering therapy, omega-3 fatty acid, and nicotinic acid